Knowledge HQ

Publications
Publications

NK-92 cellular therapy for pediatric relapsed/refractory Ewing sarcoma

Case report of a pediatric patient with relapsed Ewing sarcoma treated with intratumoral injections of NK-92 cells. NK-92 cells were expanded in GMP conditions using the G-Rex culture system. Local tumor regression was observed.
Download Now
Publications

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

Development of 'NKF' feeder cells (OCI-AML3 with mbIL-21) for NK expansion. The system allows large-scale expansion (>10,000 fold) and was validated in G-Rex. Expanded NK cells showed high cytotoxicity and metabolic activation.
Download Now
Publications

Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors

Demonstrated multiplex base editing (PDCD1, TRAC, B2M) in T cells to create allogeneic CAR-T cells. Edited cells were expanded in G-Rex vessels. The method reduced double-strand breaks and translocations compared to Cas9 nuclease.
Download Now
Publications

Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells

Study on extracellular vesicles (EVs) derived from NK cells. NK cells were propagated and activated using K562-mbIL21 aAPCs in G-Rex culture devices. NK-EVs contained cytotoxic proteins and induced cell death in cancer cells via multiple mechanisms.
Download Now
Publications

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients

Clinical trial of mRNA-engineered NKG2D CAR-NK cells in metastatic colorectal cancer. NK cells were expanded from PBMCs using K562 feeder cells in G-Rex 100 vessels. Treatment was safe and showed tumor regression in local injection sites.
Download Now
Publications

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

Patent describing the Gen 2 manufacturing process for TILs. Detailed methods include the use of G-Rex 100M and G-Rex 500M for the Rapid Expansion Protocol (REP) to shorten culture time and improve efficiency compared to the Gen 1 process.
Download Now
Publications

Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Study on gene editing T cells to place CAR and IL-12P70 under endogenous control (TRAC, IL2Ra, PDCD1). TRACCAR T cells were expanded in G-Rex 10 devices. The engineered cells showed regulated cytokine secretion and improved anti-tumor activity.
Download Now
Publications

Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T Cells

This study develops a protocol for expanding polyclonal γδ memory T cells using artificial antigen-presenting cells in G-Rex. The method yields large numbers of potent, non-alloreactive T cells with broad anti-tumor activity. This platform supports the creation of off-the-shelf immunotherapies.
Download Now
Publications

Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications

Poster describing the Iovance Gen 2 TIL manufacturing process which utilizes G-Rex for the Rapid Expansion Protocol (REP). Data shows success across melanoma, cervical, HNSCC, sarcoma, and lung cancers with high viability and T-cell purity.
Download Now
Publications

Lifileucel, a Potential Therapy for Metastatic Melanoma Patients who are Primary Refractory to Prior Anti-PD-1 Therapy

Clinical data on Lifileucel (LN-144) for metastatic melanoma. The manufacturing process involves a 22-day protocol using G-Rex. Shows 40.5% ORR in primary refractory patients.
Download Now
Publications

NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors

NKG2D.zeta-NK cells were generated and expanded in G-Rex devices. These cells eliminated myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, enhancing the infiltration and efficacy of GD2.CAR-T cells in neuroblastoma models.
Download Now
Publications

Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders

Mycobacteria-specific T cells (MSTs) were expanded from healthy donors using peptide pools and G-Rex 10. The protocol yielded polyfunctional CD4+ T cells. MSTs were largely absent in patients with primary immunodeficiencies.
Download Now

ScaleReady is a joint venture between Wilson Wolf Manufacturing and Bio-Techne.